8-K: Marker Therapeutics Reports Lymphodepletion Improves T Cell Expansion in Lymphoma Patients

Marker Therapeutics announces preliminary data from its Phase 1 APOLLO study showing that lymphodepletion enhances the expansion and persistence of MT-601 MAR-T cells in lymphoma patients.

Summary

• Marker Therapeutics reported data from the Phase 1 APOLLO study of MT-601 in lymphoma patients.
• The data suggests that lymphodepletion improves the expansion and persistence of Multi-Antigen Recognizing-T Cells (MAR-T cells).
• Objective responses were previously achieved in 7 out of 9 patients (78%), with 4 patients demonstrating complete response (CR; 44.4%) as early as 4 weeks after infusion of MT-601.
• TCR sequencing data indicates that MT-601 MAR-T cell clones expanded and persisted at significantly higher levels in patients receiving lymphodepletion.
• Patient enrollment has increased, with more patients enrolled in the first five months of 2025 than in all of 2024.
• The company expects to present clinical data from the Phase 1 APOLLO study later this year.

Sentiment

Score: 8

Explanation: The document presents positive preliminary data and increased patient enrollment, suggesting a favorable outlook for the company's lead product. The management's comments are also optimistic.

Positives

• Lymphodepletion enhances the expansion and persistence of MT-601 MAR-T cells.
• MT-601 continues to demonstrate an excellent safety profile.
• Patient enrollment is increasing, indicating growing momentum for the trial.
• Objective responses were achieved in 78% of patients, with 44.4% demonstrating complete response as early as 4 weeks after MT-601 infusion.

Risks

• The data presented is preliminary and from a Phase 1 study, so further clinical trials are needed to confirm the efficacy of MT-601.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects to present clinical data from the Phase 1 APOLLO study later this year and believes the incorporation of lymphodepletion has the potential to further enhance clinical outcomes.

Management Comments

• We are excited to see these results from our immunomonitoring study, said Juan Vera, M.D., President and CEO of Marker Therapeutics.
• Our preliminary data clearly suggests that lymphodepletion increases the expansion and persistence of MT-601 in patients.
• We believe the incorporation of lymphodepletion was the right strategic decision as demonstrated by our immunomonitoring data.
• We are now enrolling at an increased pace and are well-positioned to generate meaningful data, which we expect to share by the end of this summer, concluded Dr. Vera.

Industry Context

The announcement highlights the growing interest in T cell therapies, particularly CAR-T and MAR-T cell approaches, for treating hematological malignancies. The use of lymphodepletion to enhance T cell expansion and persistence is a common strategy in the field.

Comparison to Industry Standards

• The document references studies by Rosenberg SA, Ramos CA et al, and Turtle CJ et al, which have shown that T cell therapies can be effective with and without lymphodepletion, but lymphodepletion is associated with improved clinical outcomes and enhanced T cell expansion.
• The company compares their results to CAR-T and tumor infiltrating lymphocyte (TIL) products, suggesting they are aiming to achieve similar or better outcomes with their MAR-T cell therapy.

Stakeholder Impact

• Positive results could lead to improved treatment options for lymphoma patients.
• Increased patient enrollment could benefit clinical sites and researchers involved in the APOLLO trial.
• Successful development of MT-601 could increase shareholder value.

Next Steps

• The company plans to present clinical data from the Phase 1 APOLLO study later this year.

Key Dates

Keywords

MT-601, MAR-T cells, lymphoma, lymphodepletion, immunotherapy, Marker Therapeutics, APOLLO study, T cell therapy